Zydus receives tentative approval from the USFDA for Apremilast Tablets

Zydus receives tentative approval from the USFDA for Apremilast Tablets Ahmedabad, 16 November, 2019 Zydus Cadila has received the tentative approval from the USFDA to market Apremilast Tablets (US RLD- Otezla®) 10 mg, 20 mg, and 30 mg. This medication is used to treat a certain type of arthritis (psoriatic arthritis) and a certain type of skin condition (moderate to severe plaque psoriasis). It is also used to treat mouth sores in people who have Behcet's disease, a type of inflammatory disorder and helps to reduce the pain and improve the healing of these mouth sores. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group now has 276 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗